<DOC>
	<DOC>NCT00364793</DOC>
	<brief_summary>The primary purpose of this study is to find the dose of Efavirenz for young children. The safety and how the medication is tolerated will also be studied.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>HIV1 infected; &gt;=3 months of age to &lt;=6 years of age (at time of treatment); screening plasma viral load &gt;=1000 copies/mL Genotypic or phenotypic resistance to EFV, ddl, or FTC/lamivudine (3TC) at screening</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV, Pediatric</keyword>
</DOC>